Conditions: Hypereosinophilic Syndrome
Keywords: Mepolizumab Open-label Anti-IL-5 Hypereosinophilic Syndrome Hypereosinophilia
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 78
Healthy volunteers: no

Brief summary:
This is an open label study of mepolizumab 750 mg intravenous in those subjects who participated in study 100185 to evaluate the long term safety and efficacy of mepolizumab in subjects with hypereosinophilic syndrome. The study will also evaluate the optimal dosing frequency for clinical use, the effects on corticosteroid reduction, and decrease of signs and symptoms of Hypereosinophilic Syndrome.

Detailed description:

Arms:
arm 1: 750mg Intravenous, monthly and individual dosing schedule

Interventions: intervention 1: mepolizumab
Intervention descriptions: intervention 1: Study Drug

Protocol document: